PRKCE and neoplasm: In support, treatment with either the Cox-2 inhibitor rofecoxib or the NF-κB inhibitor parthenolide significantly abrogated tumor growth of a xenograft model using PTEN-null prostate epithelial murine cells engineered to overexpress PKCε relative to control mice [279], and long-term rofecoxib administration in a transgenic Pten+/− mouse conditionally overexpressing PKCε in the prostate epithelium inhibited tumor formation [279].